FDA Questions Capricor Drug
Capricor Stock Plummets as FDA Reviewers Question Deramiocel Efficacy and Trial Data
Anonymous
Key Points
1
The FDA's action timeline includes a July 29 advisory committee meeting to discuss deramiocel, with a PDUFA target action date of August 22, signaling a tight regulatory timeline.
2
Capricor's BLA relies on data from the Phase 3 HOPE-3 trial and the HOPE-2 long-term extension; the FDA has noted the agency previously rejected Capricor's deramiocel application in July of last year for lack of substantial evidence.
3
FDA reviewers highlighted that Capricor changed the primary endpoint from raw 42-point arm function scores to percentage changes and altered the cardiac endpoint, stating this conversion was not scientifically justified and adds complexity.
4
The agency questioned whether the enrolled patients actually had DMD-related cardiomyopathy since baseline cardiac function was normal on average, and whether enough of the intravenously delivered therapy reached the heart to plausibly produce a benefit.
5
Capricor stock experienced its biggest single-day slide and traded at its lowest level since December 2025 amid the FDA briefing documents, underscoring investor skepticism ahead of the advisory panel.
Capricor Therapeutics saw its stock collapse by roughly 67% in a single session after the FDA released briefing documents casting serious doubt on its Duchenne muscular dystrophy drug, deramiocel, according to GuruFocus. Shares fell to around $6.42, cutting the company's market value to approximately $370 million ahead of a critical advisory committee vote.
The FDA's staff reviewers raised two core questions: Did the patients in the trial actually have DMD-related heart disease? And did the IV drug actually reach the heart in meaningful amounts? Both concerns pointed toward an unfavorable benefit-risk assessment, according to TS2 Tech.
FDA Questions Whether the Drug Actually Works
FDA reviewers found no statistically significant difference between deramiocel and placebo after 12 months of treatment. The briefing documents, released ahead of the July 29 advisory committee meeting, signaled that the agency is skeptical the drug offers a real benefit, according to GuruFocus.
Reviewers also flagged that the average baseline heart function among enrolled patients was normal. That raised a direct question: If patients did not have DMD-related cardiomyopathy — a weakening of the heart muscle — how could a drug treating that condition show a meaningful effect?
Capricor Changed Key Endpoints Mid-Study, Alarming Regulators
One of the FDA's sharpest criticisms involved Capricor changing how it measured success after the trial was already underway. The company switched its primary arm-function endpoint from raw 42-point scores to percentage changes. It also altered how it measured heart function. Regulators said these changes lacked clear scientific justification.
The FDA said the post hoc — meaning after-the-fact — revisions added complexity and could reduce the accuracy of the results. This kind of endpoint change is a major red flag in drug reviews. The agency had already rejected Capricor's application for deramiocel once before, in July of last year, citing a lack of substantial evidence, according to GuruFocus.
Stock Hits Lowest Level Since December, Analyst Slashes Target
The stock fell to its lowest level since December 2025. B. Riley analyst Madison El-Saadi downgraded Capricor from Buy to Neutral and slashed her price target from $63 to $10, according to GuruFocus. That target cut alone signals how dramatically Wall Street reassessed the drug's chances overnight.
The collapse drew sharp public commentary. Martin Shkreli, the controversial former pharmaceutical executive, publicly called the company a "complete fraud" and accused CEO Linda Marbán and statistics consultant Suzanne Hendrix of manipulating data, according to Benzinga. Capricor has not publicly addressed those specific allegations.
Capricor Stands Firm, Final FDA Decision Due August 22
Despite the damaging briefing documents, Capricor said it remains confident in the overall body of evidence supporting deramiocel. The company's current application is built on data from two trials: the Phase 3 HOPE-3 study and the HOPE-2 long-term extension, according to KDH News.
The July 29 advisory committee meeting will gather outside experts to weigh in, but the panel's vote is not binding. The FDA's formal deadline to make a final decision — called the PDUFA date — is August 22. Investors and patients will be watching both dates closely.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
21
Articles
45
Reach
66
A
AnonymousAuthor
